# OnCo record nxc-201-mm (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nxc-201-mm/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nxc-201-mm", "NCT04720313" ;
  schema:name "HBI0101 (NXC-201) multiple myeloma phase 1"@en ;
  schema:alternateName "HBI0101 phase 1"@en, "NXC-201 phase 1"@en, "MOH_2020-12-22_009584"@en ;
  schema:description "Hadassah's home-made BCMA CAR-T, now called NXC-201, produced responses in three quarters of heavily pretreated myeloma patients in its first 20-patient study, with only mild cytokine release and no nerve toxicity, showing that a hospital can manufacture its own CAR-T cells."@en ;
  schema:url <https://onco.cc/trials/nxc-201-mm/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04720313>, <https://doi.org/10.3324/haematol.2022.281628> ;
  onco:status "active" ;
  onco:phase "1" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/> ;
  onco:technologies <https://onco.cc/technologies/car-t/> ;
  onco:targets <https://onco.cc/targets/bcma/> ;
  onco:drugs <https://onco.cc/drugs/nxc-201-car-t/> ;
  onco:companies <https://onco.cc/companies/immix-biopharma/> ;
  onco:institutions <https://onco.cc/institutions/hadassah/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-nxc-201-hbi0101-asherie-haematologica-2023/> .